Tag - ZVSA

Developments

ZyVersa receives European patent for VAR 200 in kidney disease

The European Patent Office granted a patent covering ZyVersa Therapeutics’ (NASDAQ:ZVSA) Phase 2a-ready Cholesterol Efflux Mediator VAR 200 for use in diabetic nephropathy/diabetic kidney disease. “Approval of this...

July 7, 2023

Feature

ZyVersa developing multiple drug therapies in renal, inflammatory diseases

ZyVersa Therapeutics (NASDAQ: ZVSA) is advancing two proprietary technologies to develop multiple, potentially transformative drugs for underserved patients with renal and inflammatory diseases.

June 13, 2023

Tag - ZVSA

ZyVersa receives European patent for VAR 200 in kidney disease

ZyVersa developing multiple drug therapies in renal, inflammatory diseases

General

More